Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings

Kekkaku

Volumn 75, Issue 11, 2000, Pages 629-641

  Yoshiyama, Takashi ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

CEA (cost effectiveness analysis); Contact tracing; Isoniazid preventive therapy; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULIN;

ARTICLE; CHEMOPROPHYLAXIS; CONTACT EXAMINATION; COST EFFECTIVENESS ANALYSIS; DEATH; DIAGNOSTIC PROCEDURE; DISABILITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; INFECTION PREVENTION; JAPAN; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; PREVALENCE; TUBERCULIN TEST;

ADULT; AGED; ANTITUBERCULAR AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, HORIZONTAL; HUMANS; ISONIAZID; JAPAN; MIDDLE AGED; MODELS, THEORETICAL; TUBERCULOSIS;

EID: 0033672794     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lincoln EM : The effect of antimicrobial therapy on the prognosis of primary tuber-culosis in children. Am Rev Tbc. 1954 ; 69 : 682-689.
2. ATS : Preventive therapy of tuberculous infection. Am Rev Respir Dis. 1974; 110: 371 - 374.
3. CDC : Screening for Tuberculosis and Tuberculosis Infection in High Risk Populations and the Use of Preventive Therapy for Tuberculous Infection in the United States. MMWR. 1990; 39 RR-8.
4. Sorresso DJ, Mehta JB, Harvill LM, et al. : Utilization of Isoniazid Chemophylaxis in Tuberculosis Contacts 50 Years of Age and Older. Chest. 1995; 108 : 706-711.
5. Salpeter SR, Sanders GD, Salpeter EE, et al. : Monitored Isoniazid Prophylaxis for Low-Risk Tuberculin Reactors Older Than 35 Years of Age : A Risk - Benefit and Cost - Effectiveness Analysis. Ann Intern Med. 1997; 127: 1051-1061.
6. Jordan TJ, Lewit EM, Reichman LB : Isoniazid Preventive Therapy for Tuberculosis. Am Rev Respir Dis. 1991; 144: 1357 - 1360.
7. Murray CJL, Lopez AD: Global Comparative Assessments in the Health Sector. WHO. 1994.
8. Comstock GW : Frost revisited, the modem epidemiology of tuberculosis. Am J Epidemiol. 1975; 101: 363-382.
9. Farebee SH: Controlled chemoprophylaxis trials in tuberculosis: a general review. Advanced in Tuberculosis Research. 1970; 17: 28-106.
10. Stead WW, To T, Harrison RW, et al. : Benefit-risk considerations in preventive therapy for tuberculosis in elderly persons. Ann Intern Med. 1987; 107: 843-845.
11. Bock NN, Metzger BS, Tapia JR : A Tuberculin Screening and Isoniazid Preventive Therapy Program in an inner-city Population. Am J Respir Grit Care Med. 1999; 159: 295-300.
12. IUAT committee on prophylaxis: Efficacy of various durations of isoniazid preventive therapy for tuberculosis five years of followup in the IUAT trial. Bull WHO. 1982; 60: 555-564.
13. Villarino ME, Rizon R, Weismuller PC, et al. : Rifampin Preventive Therapy for Tuberculosis Infection. Am J Respir Crit Care Med. 1997; 155: 1735-1738.
14. Salpeter SR : Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993; 159: 560-564.